Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.

Worboys PD, Wong SL, Barriere SL.

Eur J Clin Pharmacol. 2015 Jun;71(6):707-714. doi: 10.1007/s00228-015-1847-6. Epub 2015 May 5.

2.

Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid.

Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M.

Drug Metab Dispos. 2009 Apr;37(4):787-93. doi: 10.1124/dmd.108.024125. Epub 2008 Dec 30.

PMID:
19116265
3.

Implications and consequences of enzyme induction on preclinical and clinical drug development.

Worboys PD, Carlile DJ.

Xenobiotica. 2001 Aug-Sep;31(8-9):539-56. Review.

PMID:
11569525
4.

Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.

Renwick AB, Lewis DF, Fulford S, Surry D, Williams B, Worboys PD, Cai X, Wang RW, Price RJ, Lake BG, Evans DC.

Xenobiotica. 2001 Apr;31(4):187-204.

PMID:
11465405
5.

Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate.

Worboys PD, Bradbury A, Houston JB.

Drug Metab Dispos. 1997 Apr;25(4):460-7.

PMID:
9107546
6.
7.
8.

Supplemental Content

Loading ...
Support Center